GF 1002
Alternative Names: GF-1002Latest Information Update: 06 Feb 2024
At a glance
- Originator Genflow Biosciences
- Class Gene therapies; Hepatoprotectants
- Mechanism of Action Gene transference; SIRT6 protein expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis
Most Recent Events
- 01 Feb 2024 Genflow Biosciences plans a phase-I/II trial for Non-alcoholic steatohepatitis in Belgium in 2024
- 20 Sep 2023 Preclinical trials in Non-alcoholic steatohepatitis in United Kingdom (IV)
- 20 Sep 2023 Genflow Biosciences receives the receipt of written comments from the Federal Agency for Medicines and Health Products (FAHMP) to commence a phase I/II clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) in Belgium